查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1841972

全球臨床前影像市場：市場規模、佔有率、趨勢分析（按類型、應用、最終用途和地區）、細分市場預測（2025-2033）

Preclinical Imaging Market Size, Share & Trends Analysis Report By Type, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

臨床前影像市場摘要

臨床前影像市場預計在 2024 年價值 10 億美元，預計到 2033 年將達到 16 億美元，2025 年至 2033 年的複合年成長率為 5.6%。這一成長是由慢性病患病率上升、藥物開發投資增加以及對非侵入性成像技術的需求增加所推動的。

早期研究中採用先進的成像模式，加上不斷擴大的轉化研究舉措，進一步推動了市場擴張。政府舉措，例如美國國立衛生研究院 (NIH) 等機構以及歐洲和亞洲類似組織的津貼和資助計劃，正在為臨床前研究提供大量資金支持。例如，2022 年 9 月，NIH 和 DHHS 發布了一項研究呼籲，針對腸出血性大腸桿菌 (ETEC)、甲型副傷寒沙門氏菌和福氏志賀氏菌進行里程碑主導的臨床前疫苗開發。這些津貼用於支持創新疫苗的最佳化、生產規模擴大、安全性和有效性測試，預計在五年內每年將津貼高達 75 萬美元的資金，加速針對不同人群的候選疫苗的開發。符合資格的申請者包括高等教育機構、非營利組織、政府和公司。 NIAID計畫向四至六個計劃撥款520萬美元，用於推動疫苗進入臨床前階段並提交FDA IND申請。新增資金將使研究人員能夠購買尖端設備、開發新型成像劑，並進行更全面的臨床前研究。資金籌措的增加將直接轉化為對臨床前影像服務和技術的需求成長，從而推動市場擴張。

臨床前影像技術，例如磁振造影(MRI)、電腦斷層掃描 (CT)、正子斷層掃描 (PET)、單光子發射電腦斷層掃描(SPECT) 和超音波，提供了非侵入性方法來可視化和量化動物模型中的細胞和分子層面的生物過程。例如，2025 年 4 月《自然通訊》上的一項關於 i 型樹突狀細胞 (cDC1s) 免疫療法的研究使用 PET 成像非侵入性地監測臨床前癌症模型中的免疫反應和腫瘤動態。調查團隊使用 PET 掃描追蹤 cDC1 疫苗接種誘導的組織駐留記憶 T 細胞浸潤和活化增加，並將影像訊號與有效的腫瘤控制和復發預防關聯起來。

這種影像方法能夠即時洞察腫瘤內免疫記憶形成的時空特徵，並檢驗了超越傳統檢測方法的治療效果。這項技術對於研究人員在人體臨床試驗前研究疾病進展、評估新療法的影響以及最佳化治療策略至關重要。

同樣，在研究基礎設施完善、研發投入充足的已開發國家，這些疾病的高發生率也促使人們高度重視臨床前影像技術在治療開發中的應用，從而促進了市場的成長。此外，慢性病特異性動物模型（例如基因工程小鼠）與成像系統廣泛結合使用，這推動了對支援動態成像通訊協定的平台的需求。

阿茲海默症和帕金森氏症等神經退化性疾病也是臨床前影像應用的主要驅動力，尤其是在以中樞神經系統為重點的藥物研發領域。例如，根據阿茲海默症協會的數據，到2025年，約有720萬65歲及以上的美國人將患有阿茲海默症，其中74%的人年齡在75歲及以上。小動物PET、SPECT和MR影像技術對於追蹤小鼠模型中的蛋白質聚集、神經發炎和突觸活動至關重要。全球失智症負擔日益加重，且缺乏根治性治療方法，這促使使用先進成像技術的早期藥物篩檢計畫激增。

臨床前影像正透過人工智慧 (AI) 的應用經歷重大變革和改進。 AI 技術處理和分析產生的大量影像數據，使研究人員能夠獲得關鍵見解並加速研究進程。例如，2023 年 5 月，荷蘭皇家飛利浦公司 (Koninklijke Philips NV) 推出了飛利浦 CT 3500，這是一款創新的高通量 CT 系統，旨在滿足大規模篩檢專案和常規放射診斷的需求。飛利浦 CT 3500 具有先進的影像重建功能和工作流程改進。這些功能提供了臨床醫生所需的可靠性、速度和高品質影像，即使在充滿挑戰的醫療環境中，也能自信地診斷患者並提高操作效率。

然而，動物福利組織的規定對動物試驗的限制是阻礙市場成長的一個主要因素。這導致替代方案的採用迅速增加，例如體外測試、微劑量給藥、基於電腦的模型、新藥虛擬測試以及用於測試的電腦化資料庫的開發。然而，使用核磁共振成像 (MRI) 和電腦斷層掃描等非侵入性成像技術的手段正在逐漸進入市場。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 臨床前影像市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 臨床前影像市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章臨床前影像市場：按類型估計和趨勢分析

  • 細分儀表板
  • 全球臨床前影像市場：按類型進行的變化分析
  • 全球臨床前影像市場規模與趨勢分析（按類型）（2021-2033）
  • 情態
    • 光學成像（BLI & F）
    • 磁振造影（MRI）
    • 正子斷層掃描（PET）
    • 單光子發射電腦斷層掃描（SPECT）
    • 電腦斷層掃描（CT）
    • 超音波影像（美國）
    • 光聲成像（PAI）
    • 混合成像系統
    • 其他
  • 試劑
  • 服務

第5章臨床前影像市場：按應用的估計和趨勢分析

  • 細分儀表板
  • 全球臨床前影像市場：按應用進行的變化分析
  • 全球臨床前影像市場規模與趨勢分析（按應用）（2021-2033）
  • 藥物發現與開發
  • 毒理學和藥物動力學研究
  • 基礎研究、轉化研究
  • 疾病機轉及病理學研究
    • 腫瘤學
    • 心臟病學
    • 神經病學
    • 感染疾病
    • 免疫學和炎症
    • 其他
  • 生物標記和造影劑的檢驗
  • 其他

6. 臨床前影像市場：依最終用途的估計和趨勢分析

  • 細分儀表板
  • 全球臨床前成像市場：按最終用途進行的變化分析
  • 全球臨床前影像市場規模和趨勢分析（按最終用途）（2021-2033）
  • 製藥和生物技術公司
  • CRO（委外研發機構）
  • 學術研究機構
  • 其他

第7章臨床前影像市場：區域估計和趨勢分析（按類型、應用和最終用途）

  • 2025年及2033年區域市佔率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 市場規模、預測趨勢分析，2021-2033年：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 2025年主要企業市佔率分析
  • Company Position Analysis
  • 公司分類（新興企業、創新企業、領導者）
  • 公司簡介
    • Cubresa Inc.
    • Bruker Corporation
    • Revvity（PerkinElmer, Inc）
    • FUJIFILM VisualSonics
    • Mediso Ltd.
    • Rigaku（MILabs BV）
    • MR Solutions
    • Aspect Imaging
    • TriFoil Imaging
    • Siemens Healthineers
Product Code: 978-1-68038-881-7

Preclinical Imaging Market Summary

The preclinical imaging market size was estimated at USD 1.0 billion in 2024 and is expected to reach USD 1.6 billion by 2033, growing at a CAGR of 5.6% from 2025 to 2033. This growth is driven by the rising prevalence of chronic diseases, increasing investments in drug development, and growing demand for non-invasive imaging techniques.

The adoption of advanced imaging modalities for early-stage research, coupled with the expansion of translational research initiatives, further accelerates market expansion. Government initiatives, such as grants and funding programs from agencies such as the National Institutes of Health (NIH) in the U.S. and similar organizations in Europe and Asia, are providing substantial financial support for preclinical research. For instance, in September 2022, the NIH and DHHS invited research applications for milestone-driven preclinical vaccine development targeting Enterotoxigenic Escherichia coli (ETEC), Salmonella Paratyphi A, and Shigella species. The funding supported innovative vaccine optimization, production scale-up, safety, and efficacy testing, with up to USD 750,000/year over five years, aiming to accelerate candidate vaccines for diverse populations. Eligible applicants included higher education institutions, nonprofits, governments, and businesses. NIAID planned to award USD 5.2 million for 4-6 projects to advance vaccines through preclinical stages toward FDA IND submission. Such a rise of capital enables researchers to acquire cutting-edge equipment, develop novel imaging agents, and conduct more comprehensive preclinical studies. The increased availability of funding directly translates into a higher demand for preclinical imaging services and technologies, thereby driving market expansion.

Preclinical imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and ultrasound, offer non-invasive methods to visualize and quantify biological processes at the cellular and molecular levels in animal models. For instance, an April 2025 Nature Communications study on type I conventional dendritic cells (cDC1s) immunotherapy used PET imaging to noninvasively monitor immune responses and tumor dynamics in preclinical cancer models. Researchers used PET scans to track the enhanced infiltration and activation of tissue-resident memory T cells induced by cDC1 vaccination, correlating imaging signals with effective tumor control and relapse prevention.

This imaging approach provided real-time insights into the spatial and temporal aspects of immune memory formation within tumors, validating the therapy's efficacy beyond conventional assays. This capability is crucial for researchers to study disease progression, assess the impact of novel therapies, and optimize treatment strategies before clinical trials in humans.

Similarly, the high prevalence of these diseases in developed countries with well established research infrastructures and investment in R&D significantly boosts the focus on preclinical imaging for treatment development, thereby contributing to the market growth. Additionally, chronic disease-specific animal models such as genetically engineered mice are being used extensively in combination with imaging systems, increasing the need for platforms that support dynamic imaging protocols.

Neurodegenerative diseases such as Alzheimer's and Parkinson's are also key drivers for the adoption of preclinical imaging, particularly in CNS-focused drug discovery. For instance, according to the Alzheimer's Association, around 7.2 million Americans aged 65 years and above in the America have Alzheimer's in 2025, with 74% among these being aged of age 75 years or above. Small-animal PET, SPECT, and MR imaging modalities are critical in tracking protein aggregation, neuroinflammation, and synaptic activity in murine models. The rising global burden of dementia and the lack of curative therapies have contributed to the surge in early-stage drug screening programs using advanced imaging techniques.

Preclinical imaging has experienced significant transformation and improvement through the use of AI (Artificial Intelligence). The vast amount of imaging data generated is processed and analyzed with AI techniques, enabling researchers to gain important insights and accelerate their work. For example, in May 2023, Koninklijke Philips N.V. introduced the Philips CT 3500, an innovative high-throughput CT system designed to meet the needs of large-scale screening programs and routine radiology. The Philips CT 3500 features advanced image reconstruction capabilities and workflow improvements. These features provide the reliability, speed, and high-quality imaging needed for clinicians to confidently diagnose patients and enhance operational efficiency, even in challenging medical environments.

On the other hand, the restrictions placed on animal testing due to regulations enforced by organizations that protect animal rights are the major factors impeding the growth of the market. Therefore, the adoption of alternative methods, such as in-vitro tests, micro-dosing, computer-based models, virtual testing of new drugs, and the development of computerized databases for testing purposes, is rapidly increasing. However, modalities with non-invasive imaging techniques such as MRI and CT scans are making their way into the market.

Global Preclinical Imaging Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global preclinical imaging market on the basis of type, application, end use and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Modality
    • Optical Imaging (BLI & F)
    • Magnetic Resonance Imaging (MRI)
    • Positron Emission Tomography (PET)
    • Single Photon Emission Computed Tomography (SPECT)
    • Computed Tomography (CT)
    • Ultrasound Imaging (US)
    • Photoacoustic Imaging (PAI)
    • Hybrid Imaging Systems
    • Bi-Modal
    • SPECT-CT
    • PET-CT
    • SPECT-PET
    • PET-MRI
    • Optical-CT
    • Others
    • Tri-Modal
    • PET-SPECT-CT
    • PET-SPECT-MRI
    • PET-CT-Optical
    • Others
    • Others
  • Reagent
  • Service
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Drug Discovery & Development
  • Toxicology & Pharmacokinetics Studies
  • Basic & Translational Research
  • Disease Mechanism & Pathophysiology Studies
    • Oncology
    • Cardiology
    • Neurology
    • Infectious Diseases
    • Immunology & Inflammation
    • Others
  • Biomarker & Imaging Agent Validation
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharma and Biotech Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Application outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Preclinical Imaging Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Preclinical Imaging Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Preclinical Imaging Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Preclinical Imaging Type Market Movement Analysis
  • 4.3. Global Preclinical Imaging Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Modality
    • 4.4.1. Modality market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Optical Imaging (BLI & F)
      • 4.4.2.1. Optical Imaging (BLI & F) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Magnetic Resonance Imaging (MRI)
      • 4.4.3.1. Magnetic Resonance Imaging (MRI) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Positron Emission Tomography (PET)
      • 4.4.4.1. Positron Emission Tomography (PET) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5. Single Photon Emission Computed Tomography (SPECT)
      • 4.4.5.1. Single Photon Emission Computed Tomography (SPECT) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6. Computed Tomography (CT)
      • 4.4.6.1. Computed Tomography (CT) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7. Ultrasound Imaging (US)
      • 4.4.7.1. Ultrasound Imaging (US) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8. Photoacoustic Imaging (PAI)
      • 4.4.8.1. Photoacoustic Imaging (PAI) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.9. Hybrid Imaging Systems
      • 4.4.9.1. Hybrid Imaging Systems market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.2. Bi-Modal
        • 4.4.9.2.1. Bi-Modal market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.2. SPECT-CT
          • 4.4.9.2.2.1. SPECT-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.3. PET-CT
          • 4.4.9.2.3.1. PET-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.4. SPECT-PET
          • 4.4.9.2.4.1. SPECT-PET market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.5. PET-MRI
          • 4.4.9.2.5.1. PET-MRI market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.6. Optical-CT
          • 4.4.9.2.6.1. Optical-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.7. Others
          • 4.4.9.2.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.3. Tri-Modal
        • 4.4.9.3.1. Tri-Modal market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.2. PET-SPECT-CT
          • 4.4.9.3.2.1. PET-SPECT-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.3. PET-SPECT-MRI
          • 4.4.9.3.3.1. PET-SPECT-MRI market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.4. PET-CT-Optical
          • 4.4.9.3.4.1. PET-CT-Optical market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.5. Others
          • 4.4.9.3.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.10. Others
      • 4.4.10.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Reagent
    • 4.5.1. Reagent market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Service
    • 4.6.1. Service market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Preclinical Imaging Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Preclinical Imaging Application Market Movement Analysis
  • 5.3. Global Preclinical Imaging Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.4. Drug Discovery & Development
    • 5.4.1. Drug Discovery & Development market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Toxicology & Pharmacokinetics Studies
    • 5.5.1. Toxicology & Pharmacokinetics Studies market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Basic & Translational Research
    • 5.6.1. Basic & Translational Research market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Disease Mechanism & Pathophysiology Studies
    • 5.7.1. Disease Mechanism & Pathophysiology Studies market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.2. Oncology
      • 5.7.2.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.3. Cardiology
      • 5.7.3.1. Cardiology market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.4. Neurology
      • 5.7.4.1. Neurology market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.5. Infectious Diseases
      • 5.7.5.1. Infectious Diseases market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.6. Immunology & Inflammation
      • 5.7.6.1. Immunology & Inflammation market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.7. Others
      • 5.7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.8. Biomarker & Imaging Agent Validation
    • 5.8.1. Biomarker & Imaging Agent Validation market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Preclinical Imaging Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Preclinical Imaging End Use Market Movement Analysis
  • 6.3. Global Preclinical Imaging Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Pharma and Biotech Companies
    • 6.4.1. Pharma and biotech companies market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Contract Research Organizations (CROs)
    • 6.5.1. Contract Research Organizations (CROs) market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Academic and Research Institutes
    • 6.6.1. Academic and Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Preclinical Imaging Market: Regional Estimates & Trend Analysis By Type, Application, End Use

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. Reimbursement structure
      • 7.5.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement structure
      • 7.5.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement structure
      • 7.5.3.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Reimbursement structure
      • 7.6.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement structure
      • 7.6.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement structure
      • 7.6.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Reimbursement structure
      • 7.6.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Reimbursement structure
      • 7.6.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Reimbursement structure
      • 7.6.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Reimbursement structure
      • 7.6.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Competitive scenario
      • 7.6.8.3. Regulatory framework
      • 7.6.8.4. Reimbursement structure
      • 7.6.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Reimbursement structure
      • 7.7.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement structure
      • 7.7.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement structure
      • 7.7.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement structure
      • 7.7.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Reimbursement structure
      • 7.7.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Competitive scenario
      • 7.7.6.3. Regulatory framework
      • 7.7.6.4. Reimbursement structure
      • 7.7.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. Reimbursement structure
      • 7.8.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Reimbursement structure
      • 7.8.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Competitive scenario
      • 7.9.1.3. Regulatory framework
      • 7.9.1.4. Reimbursement structure
      • 7.9.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Competitive scenario
      • 7.9.2.3. Regulatory framework
      • 7.9.2.4. Reimbursement structure
      • 7.9.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Competitive scenario
      • 7.9.3.3. Regulatory framework
      • 7.9.3.4. Reimbursement structure
      • 7.9.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Competitive scenario
      • 7.9.4.3. Regulatory framework
      • 7.9.4.4. Reimbursement structure
      • 7.9.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Key company market share analysis, 2025
  • 8.4. Company Position Analysis
  • 8.5. Company Categorization (Emerging Players, Innovators and Leaders)
  • 8.6. Company Profiles
    • 8.6.1. Cubresa Inc.
      • 8.6.1.1. Company overview
      • 8.6.1.2. Financial performance
      • 8.6.1.3. Product benchmarking
      • 8.6.1.4. Strategic initiatives
    • 8.6.2. Bruker Corporation
      • 8.6.2.1. Company overview
      • 8.6.2.2. Financial performance
      • 8.6.2.3. Product benchmarking
      • 8.6.2.4. Strategic initiatives
    • 8.6.3. Revvity (PerkinElmer, Inc)
      • 8.6.3.1. Company overview
      • 8.6.3.2. Financial performance
      • 8.6.3.3. Product benchmarking
      • 8.6.3.4. Strategic initiatives
    • 8.6.4. FUJIFILM VisualSonics
      • 8.6.4.1. Company overview
      • 8.6.4.2. Financial performance
      • 8.6.4.3. Product benchmarking
      • 8.6.4.4. Strategic initiatives
    • 8.6.5. Mediso Ltd.
      • 8.6.5.1. Company overview
      • 8.6.5.2. Financial performance
      • 8.6.5.3. Product benchmarking
      • 8.6.5.4. Strategic initiatives
    • 8.6.6. Rigaku (MILabs B.V.)
      • 8.6.6.1. Company overview
      • 8.6.6.2. Financial performance
      • 8.6.6.3. Product benchmarking
      • 8.6.6.4. Strategic initiatives
    • 8.6.7. MR Solutions
      • 8.6.7.1. Company overview
      • 8.6.7.2. Financial performance
      • 8.6.7.3. Product benchmarking
      • 8.6.7.4. Strategic initiatives
    • 8.6.8. Aspect Imaging
      • 8.6.8.1. Company overview
      • 8.6.8.2. Financial performance
      • 8.6.8.3. Product benchmarking
      • 8.6.8.4. Strategic initiatives
    • 8.6.9. TriFoil Imaging
      • 8.6.9.1. Company overview
      • 8.6.9.2. Financial performance
      • 8.6.9.3. Product benchmarking
      • 8.6.9.4. Strategic initiatives
    • 8.6.10. Siemens Healthineers
      • 8.6.10.1. Company overview
      • 8.6.10.2. Financial performance
      • 8.6.10.3. Product benchmarking
      • 8.6.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America preclinical imaging market, By country, 2021 - 2033 (USD Million)
  • Table 3 North America preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 4 North America preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 5 North America preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 6 U.S. preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 7 U.S. preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 8 U.S. preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 9 Canada preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 10 Canada preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 11 Canada preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 12 Mexico preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 13 Mexico preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 14 Mexico preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 15 Europe preclinical imaging market, By country, 2021 - 2033 (USD Million)
  • Table 16 Europe preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 17 Europe preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 18 Europe preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 19 UK preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 20 UK preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 21 UK preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 22 Germany preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 23 Germany preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 24 Germany preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 25 France preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 26 France preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 27 France preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 28 Italy preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 29 Italy preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 30 Italy preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 31 Denmark preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 32 Denmark preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 33 Denmark preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 34 Sweden preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 35 Sweden preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 36 Sweden preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 37 Norway preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 38 Norway preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 39 Norway preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 40 Asia Pacific preclinical imaging market, By country, 2021 - 2033 (USD Million)
  • Table 41 Asia Pacific preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 42 Asia Pacific preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 44 Japan preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 45 Japan preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 46 Japan preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 47 China preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 48 China preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 49 China preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 50 India preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 51 India preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 52 India preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 53 Australia preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 54 Australia preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 55 Australia preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 56 South Korea preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 57 South Korea preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 58 South Korea preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 59 Thailand preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 60 Thailand preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 61 Thailand preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 62 Latin America preclinical imaging market, By Country, 2021 - 2033 (USD Million)
  • Table 63 Latin America preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 64 Latin America preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 65 Latin America preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 66 Brazil preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 67 Brazil preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 68 Brazil preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 69 Argentina preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 70 Argentina preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 71 Argentina preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 72 Middle East & Africa preclinical imaging market, By country, 2021 - 2033 (USD Million)
  • Table 73 Middle East & Africa preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 74 Middle East & Africa preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 75 Middle East & Africa preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 76 South Africa preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 77 South Africa preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 78 South Africa preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 79 Saudi Arabia preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 80 Saudi Arabia preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 81 Saudi Arabia preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 82 UAE preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 83 UAE preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 84 UAE preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 85 Kuwait preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 86 Kuwait preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 87 Kuwait preclinical imaging market, By end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Preclinical imaging market: Market outlook
  • Fig. 14 Preclinical imaging market competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Preclinical imaging market driver impact
  • Fig. 20 Preclinical imaging restraint impact
  • Fig. 21 Preclinical imaging market: type movement analysis
  • Fig. 22 Preclinical imaging market: type outlook and key takeaways
  • Fig. 23 Modality market estimates and forecast, 2021 - 2033
  • Fig. 24 Optical Imaging (BLI & F) market estimates and forecast, 2021 - 2033
  • Fig. 25 MRI market estimates and forecast, 2021 - 2033
  • Fig. 26 PET market estimates and forecast, 2021 - 2033
  • Fig. 27 SPECT market estimates and forecast, 2021 - 2033
  • Fig. 28 CT market estimates and forecast, 2021 - 2033
  • Fig. 29 Ultrasound Imaging (US) market estimates and forecast, 2021 - 2033
  • Fig. 30 Photoacoustic Imaging (PAI) market estimates and forecast, 2021 - 2033
  • Fig. 31 Hybrid Imaging Systems market estimates and forecast, 2021 - 2033
  • Fig. 32 Bi-Modal market estimates and forecast, 2021 - 2033
  • Fig. 33 SPECT-CT market estimates and forecast, 2021 - 2033
  • Fig. 34 PET-CT market estimates and forecast, 2021 - 2033
  • Fig. 35 SPECT-PET market estimates and forecast, 2021 - 2033
  • Fig. 36 PET-MRI market estimates and forecast, 2021 - 2033
  • Fig. 37 Optical-CT market estimates and forecast, 2021 - 2033
  • Fig. 38 Others market estimates and forecast, 2021 - 2033
  • Fig. 39 Tri-Modal market estimates and forecast, 2021 - 2033
  • Fig. 40 PET-SPECT-CT market estimates and forecast, 2021 - 2033
  • Fig. 41 PET-SPECT-MRI market estimates and forecast, 2021 - 2033
  • Fig. 42 PET-CT-Optical market estimates and forecast, 2021 - 2033
  • Fig. 43 Others market estimates and forecast, 2021 - 2033
  • Fig. 44 Reagents market estimates and forecast, 2021 - 2033
  • Fig. 45 Services market estimates and forecast, 2021 - 2033
  • Fig. 46 Preclinical imaging market: application movement analysis
  • Fig. 47 Preclinical imaging market: application outlook and key takeaways
  • Fig. 48 Drug Discovery & Development market estimates and forecast, 2021 - 2033
  • Fig. 49 Toxicology & Pharmacokinetics Studies market estimates and forecast, 2021 - 2033
  • Fig. 50 Basic & Translational Research market estimates and forecast, 2021 - 2033
  • Fig. 51 Disease Mechanism & Pathophysiology Studies market estimates and forecast, 2021 - 2033
  • Fig. 52 Oncology market estimates and forecast, 2021 - 2033
  • Fig. 53 Cardiology market estimates and forecast, 2021 - 2033
  • Fig. 54 Neurology market estimates and forecast, 2021 - 2033
  • Fig. 55 Infectious Diseases market estimates and forecast, 2021 - 2033
  • Fig. 56 Immunology & Inflammation market estimates and forecast, 2021 - 2033
  • Fig. 57 Others market estimates and forecast, 2021 - 2033
  • Fig. 58 Biomarker & Imaging Agent Validation market estimates and forecast, 2021 - 2033
  • Fig. 59 Others market estimates and forecast, 2021 - 2033
  • Fig. 60 Preclinical imaging market: end use movement analysis
  • Fig. 61 Preclinical imaging market: end use outlook and key takeaways
  • Fig. 62 Pharma and biotech companies market estimates and forecast, 2021 - 2033
  • Fig. 63 Contract Research Organizations (CROs) market estimates and forecast, 2021 - 2033
  • Fig. 64 Academic and Research Institutes market estimates and forecast, 2021 - 2033
  • Fig. 65 Others market estimates and forecast, 2021 - 2033
  • Fig. 66 Global Preclinical Imaging Market: regional movement analysis
  • Fig. 67 Global Preclinical Imaging Market: regional outlook and key takeaways
  • Fig. 68 North America
  • Fig. 69 North America market estimates and forecast, 2021 - 2033
  • Fig. 70 U.S.
  • Fig. 71 U.S. market estimates and forecast, 2021 - 2033
  • Fig. 72 Canada
  • Fig. 73 Canada market estimates and forecast, 2021 - 2033
  • Fig. 74 Mexico
  • Fig. 75 Mexico market estimates and forecast, 2021 - 2033
  • Fig. 76 Europe
  • Fig. 77 Europe. market estimates and forecast, 2021 - 2033
  • Fig. 78 UK
  • Fig. 79 UK market estimates and forecast, 2021 - 2033
  • Fig. 80 Germany
  • Fig. 81 Germany market estimates and forecast, 2021 - 2033
  • Fig. 82 France
  • Fig. 83 France market estimates and forecast, 2021 - 2033
  • Fig. 84 Italy
  • Fig. 85 Italy market estimates and forecast, 2021 - 2033
  • Fig. 86 Spain
  • Fig. 87 Spain market estimates and forecast, 2021 - 2033
  • Fig. 88 Denmark
  • Fig. 89 Denmark market estimates and forecast, 2021 - 2033
  • Fig. 90 Sweden
  • Fig. 91 Sweden market estimates and forecast, 2021 - 2033
  • Fig. 92 Norway
  • Fig. 93 Norway market estimates and forecast, 2021 - 2033
  • Fig. 94 Asia Pacific
  • Fig. 95 Asia Pacific market estimates and forecast, 2021 - 2033
  • Fig. 96 Japan
  • Fig. 97 Japan market estimates and forecast, 2021 - 2033
  • Fig. 98 China
  • Fig. 99 China market estimates and forecast, 2021 - 2033
  • Fig. 100 India
  • Fig. 101 India market estimates and forecast, 2021 - 2033
  • Fig. 102 South Korea
  • Fig. 103 South Korea market estimates and forecast, 2021 - 2033
  • Fig. 104 Thailand
  • Fig. 105 Thailand market estimates and forecast, 2021 - 2033
  • Fig. 106 Australia
  • Fig. 107 Australia market estimates and forecast, 2021 - 2033
  • Fig. 108 Latin America
  • Fig. 109 Latin America market estimates and forecast, 2021 - 2033
  • Fig. 110 Brazil
  • Fig. 111 Brazil market estimates and forecast, 2021 - 2033
  • Fig. 112 Argentina
  • Fig. 113 Argentina market estimates and forecast, 2021 - 2033
  • Fig. 114 Middle East and Africa
  • Fig. 115 Middle East and Africa. market estimates and forecast, 2021 - 2033
  • Fig. 116 Saudi Arabia
  • Fig. 117 Saudi Arabia market estimates and forecast, 2021 - 2033
  • Fig. 118 South Africa
  • Fig. 119 South Africa market estimates and forecast, 2021 - 2033
  • Fig. 120 UAE
  • Fig. 121 UAE market estimates and forecast, 2021 - 2033
  • Fig. 122 Kuwait
  • Fig. 123 Kuwait market estimates and forecast, 2021 - 2033
  • Fig. 124 Participant categorization- Preclinical imaging market
  • Fig. 125 Market share of key market players- Preclinical imaging market